Treasury Draft Rules Hit China Biotech Equity Deals, Spare Licensing

Treasury's Oct. 22 draft rules ban U.S. equity stakes in Chinese biotech but spare licensing deals, leaving Pfizer's $10.5 billion Innovent agreement in a regulatory gray zone.